Skip to content

Study · Systematic review · 2021

2 results

Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.

Kong QX, Ruan Q, Fan C, Liu BL, Reng LP, Xu W

Endokrynologia Polska19 May 2021Cited by 18 (Europe PMC)

PMID34010433 (opens in a new tab)DOI10.5603/ep.a2021.0031 (opens in a new tab)PepBankPUB-34010433
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewSafety outcome

    In patients with type 2 diabetes, liraglutide 1.8 mg per day reduced fracture risk in the subgroup analysis (OR 0.621, 95% CI 0.413-0.933).

    In plain wordsIn people with type 2 diabetes, liraglutide 1.8 mg per day was linked to fewer fractures in a subgroup of trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseFracture risk with liraglutide 1.8 mg per day
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.8 mg per dayAs given in this study (human).

    Measurements

    OR fracture
    0.621
    liraglutide 1.8 mg per day

    Source sentences

    Summary
    But in the subgroup analysis, when sitagliptin 100 mg per day (OR 0.495, 95% CI: 0.304-0.806) or liraglutide 1.8 mg per day was administered (OR 0.621, 95% CI: 0.413-0.933)
    1 context sentence
    Summary · context
    Multiple databases were searched for original articles that investigated the relationship between the use of incretin agents and fracture risk, up to December 2019.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In patients with type 2 diabetes, pooled incretins (DPP4 inhibitors and GLP1 receptor agonists, including liraglutide) were not associated with fracture risk (0.97, 95% CI 0.88-1.08).

    In plain wordsIn people with type 2 diabetes, incretin drugs as a group were not linked to more fractures.

    Peptide
    Liraglutide
    Outcome
    No significant changeFracture risk with incretins
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Fracture risk estimate
    0.97
    pooled incretins

    Source sentences

    Summary
    Incretins were not associated with fracture risk [0.97 (95% CI: 0.88-1.08)].
    1 context sentence
    Summary · context
    Multiple databases were searched for original articles that investigated the relationship between the use of incretin agents and fracture risk, up to December 2019.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.